MOD GRF 1-29 - Research Grade Peptide

MOD GRF 1-29 – Research-Grade Synthetic Peptide

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, consumption, clinical use or therapeutic application. It must not be used in any way that contravenes applicable laws or the requirements of the Medicines and Healthcare products Regulatory Agency.

• Research-grade synthetic 29-residue peptide with batch documentation available where supplied
• Defined MOD GRF 1-29 sequence containing four specified amino-acid substitutions
• C-terminally amidated structure without the additional C-terminal DAC-associated modification
• Supplied as lyophilised laboratory material in sealed flip-top headspace vials
• Batch identity, chromatographic purity, peptide content and analytical specifications stated in the applicable Certificate of Analysis
• Handled and supplied exclusively as a research-use laboratory material

All of our research peptides and related laboratory materials are supplied strictly for scientific research and laboratory use only. Each vial contains lyophilised material prepared to support controlled laboratory handling and storage. The stated nominal amount refers to the declared MOD GRF 1-29 peptide content of a single vial, subject to the applicable batch documentation. Where dissolution or reconstitution is required, the solvent, buffer, concentration, handling procedure and storage conditions stated in the applicable Certificate of Analysis, Safety Data Sheet or validated laboratory method should be followed. We do not provide advice or recommendations concerning dosage, administration or use in humans or animals.

Chemical and Structural Information:

• Product Name: MOD GRF 1-29
• Preferred Technical Description: Modified GRF (1–29)
• Alternative Names: MOD GRF 1-29; Modified GRF 1–29; Modified Growth Hormone-Releasing Factor 1–29; CJC-1295 Without DAC; CJC-1295 No DAC; tetrasubstituted GRF 1–29
• Material Classification: Synthetic linear 29-residue peptide
• Sequence Length: 29 amino-acid residues
• Peptide Sequence: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
• Sequence Shorthand: Y-[D-Ala]-DAIFTQSYRKVLAQLSARKLLQDILSR-NH₂
• Sequence Modifications: D-alanine at position 2, glutamine at position 8, alanine at position 15 and leucine at position 27
• N-Terminal Structure: Free tyrosine amino terminus
• C-Terminal Structure: C-terminal argininamide
• DAC Status: Does not contain the additional C-terminal maleimidopropionyl-lysine modification associated with the separate DAC-containing molecular structure
• Commonly Assigned CAS Number: 863288-34-0
• PubChem Compound Identifier: CID 56841945
• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Average Molecular Weight: Approximately 3367.95 g/mol
• Elemental-Composition Note: The MOD GRF 1-29 sequence contains no cysteine or methionine residue and its reference molecular formula therefore contains no sulphur
• Formula Basis: The molecular formula and molecular weight describe the uncountered, C-terminally amidated MOD GRF 1-29 molecular structure without acetate, trifluoroacetate, residual water, formulation excipients or other batch-dependent components
• Physical Form: Lyophilised laboratory material, as stated in the applicable batch Certificate of Analysis
• Appearance: White to off-white laboratory material, subject to confirmation in the applicable batch Certificate of Analysis
• Purity Specification: The applicable chromatographic purity result, analytical method and acceptance criterion are stated in the batch Certificate of Analysis
• Peptide-Content Specification: Net MOD GRF 1-29 peptide content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion, residual-solvent and formulation results
• Sequence Confirmation: The complete 29-residue sequence and four specified substitutions should be confirmed using the applicable synthesis and batch records
• Stereochemical Confirmation: The D-alanine residue at position 2 should be supported by suitable synthesis records or stereochemical analytical documentation
• Terminal-Structure Confirmation: Molecular-identity documentation should confirm the C-terminal argininamide structure
• Mass-Spectrometry Confirmation: Molecular identity should be supported by analytical mass data consistent with the specified approximately 3367.95 Da MOD GRF 1-29 structure
• Chemical-Form Confirmation: The applicable Certificate of Analysis should identify whether the supplied laboratory material is the uncountered peptide, an acetate form, a trifluoroacetate form or another counter-ion form
• Counter-Ion Confirmation: Acetate, trifluoroacetate or another counter-ion may affect the total measured material mass, water content and net peptide content of the supplied laboratory material
• Residual-Solvent Specification: Applicable residual solvents arising from peptide synthesis, cleavage and chromatographic purification should be stated or controlled through the batch specification
• Related-Impurity Control: Deletion sequences, incompletely deprotected material, stereochemical impurities, oxidation products and other synthesis-related or process-related impurities are separate quality attributes
• Endotoxin Specification: The applicable bacterial endotoxin or LPS result, analytical method, reporting units, method-suitability controls and acceptance criterion should be stated in the batch Certificate of Analysis
• Analytical Interpretation: Molecular identity, amino-acid sequence, stereochemistry, terminal structure, chromatographic purity, net peptide content, water content, residual solvents, counter-ion content and bacterial endotoxin results are separate analytical measurements and should be interpreted together

✓ Batch documentation – Completed Certificate of Analysis documentation is provided where supplied for review.
✓ Certificate of Analysis – Accessible through the product QR code where provided for the applicable batch.
✓ Safety Data Sheet – Supplied to support appropriate laboratory handling, storage and regulatory compliance.
✓ Sequence documentation – The complete 29-residue amino-acid sequence and four specified substitutions should be confirmed using the applicable batch records.
✓ Stereochemical documentation – The D-alanine residue should be supported by appropriate synthesis or analytical documentation.
✓ Terminal-structure documentation – The C-terminal argininamide structure should be confirmed using the applicable molecular-identity records.
✓ Mass-spectrometry documentation – Molecular identity should be supported by analytical mass data consistent with the specified MOD GRF 1-29 structure.
✓ Purity documentation – The reported chromatographic purity applies only to the analytical method and batch stated in the Certificate of Analysis.
✓ Peptide-content documentation – Net MOD GRF 1-29 peptide content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion and residual-solvent results.
✓ Chemical-form documentation – The uncountered peptide, acetate form, trifluoroacetate form or other counter-ion form should be identified clearly in the applicable product and batch records.
✓ Bacterial endotoxin documentation – The applicable bacterial endotoxin or LPS result should identify the test method, reporting units, method-suitability controls and acceptance criterion.
✓ Supplier documentation – Reviewed where supporting synthesis, purification and analytical records are supplied.
✓ Fast, reliable and trackable express delivery – Securely packaged and dispatched using insulated or temperature-managed packaging where required by the applicable transport and storage specification.

For Research Use Only
This product is supplied strictly for scientific research, laboratory analysis and experimental work. It is not intended for human consumption, animal use, clinical use, diagnostic use or any form of therapeutic application.

MOD GRF 1-29 Product Overview

Our MOD GRF 1-29 research-grade synthetic peptide is supplied for controlled scientific laboratory investigation, analytical method development, peptide characterisation, high-performance liquid chromatography assessment, mass-spectrometry workflows and reference-material comparison. The material comprises a defined linear sequence of 29 amino-acid residues containing four specified sequence modifications and a C-terminal amide.

The reference sequence incorporates D-alanine at position 2, glutamine at position 8, alanine at position 15 and leucine at position 27. The material does not contain the additional C-terminal maleimidopropionyl-lysine modification associated with the separate DAC-containing molecular structure.

The material is handled with a focus on batch traceability, documented quality control and consistent laboratory presentation. Product identity, amino-acid sequence, stereochemical configuration, terminal structure, chromatographic purity, net peptide content, molecular form, counter-ion content, water content, residual solvents, bacterial endotoxin results and other analytical specifications should be confirmed using the applicable batch Certificate of Analysis.

The molecular formula C₁₅₂H₂₅₂N₄₄O₄₂ and average molecular weight of approximately 3367.95 g/mol describe the uncountered, C-terminally amidated MOD GRF 1-29 molecular structure. Where the supplied laboratory material contains acetate, trifluoroacetate or another counter-ion, the applicable batch documentation should identify the counter-ion content and whether the stated vial quantity is expressed as net peptide equivalent or total supplied material.

Chromatographic purity should not automatically be interpreted as equivalent to total net peptide content. Likewise, a bacterial endotoxin or LPS result does not establish sterility, molecular identity, correct stereochemistry, sequence integrity, terminal amidation or the absence of every synthesis-related and process-related impurity.

For the majority of routine analytical, investigative, peptide-characterisation and general laboratory work, the Regular MOD GRF 1-29 specification remains highly suitable. The premium black-and-gold ULTIMATE MOD GRF 1-29 option provides an additional preparative high-performance liquid chromatography purification stage and a more stringent bacterial endotoxin and lipopolysaccharide testing specification for scientific projects requiring enhanced quality-control parameters.

View Certificate of Analysis

View Safety Data Sheet